<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='1'><Row><ArmCount>1</ArmCount><Biomarkers>APOE epsilon4; Abeta; Complement factor I; P-tau; tau</Biomarkers><Condition>Alzheimers disease</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="57403">GSK-933776A</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>GSK-933776A</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK-933776) in Patients With Alzheimer's Disease</ProtocolTitle><Reference>106006; 2006-004014-41; BA1106006; NCT00459550</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="1"/><TrialStartDate>MARCH    , 12, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row></Rowset>